To assess the cost-effectiveness of paroxetine (PX) compared with conventional tricyclic antidepressants (TCA's) for major depressive disorder in Japan. METHODS: A decision analytic model was built in order to compare three regimens: 1) initiating with PX followed by a TCA (PX-TCA's); 2) a TCA followed by PX (TCA's-PX); and 3) TCA's only. The decision tree incorporated the probabilities of dropping out of therapy obtained from a meta-analysis of randomized controlled trials in Japan, and also relapse or recurrence probabilities of depressive symptoms employed from published literature. Resource use and costs were estimated by the national health insurance (NHI) scoring system. Health related quality of life was incorporated in the model using utility values in the literature. The analysis was performed from a patient perspective during nine months including the follow-up period. The sensitivity analyses were conducted to test the robustness of the results. RESULTS: The average costs per patient for each regimen of the PX-TCA's, the TCA's-PX and the only TCA's were estimated with 4676€, 4541€ and 5045€, respectively. Regarding the utility analysis, the PX-TCA's best contributed to gain with incremental cost-effectiveness ratio of 5587€/QALY. The average cost per patient for each regimen of the PX-TCA's or the TCA's-PX remained lower than that of the only TCA's over the ranges of the sensitivity analyses. CONCLUSIONS: A treatment for major depression using PX combined with TCA's was cost-saving in terms of average costs per patient, comparing to the treatment by the TCA's alone. The first choice of PX did not reduce the average cost towards the first choice of TCA's in the combined treatment. When quality of life of patients incorporated, the first choice of PX was best recommended among the three strategies. 5 Eli Lilly, The Netherlands OBJECTIVES: The objective of this study is to estimate the Health Related Quality of Life (HRQoL) of ADHD children and the societal costs for The Netherlands. METHODS: An initial population of 10,000 children aged 6-8 years were rated by their schoolteachers to determine the probability of ADHD. A total of 150 children with low scores (low probability) and 150 with high scores were invited for a detailed prospective assessment of the burden of illness for patient and relatives. We collected data from the mother on health care utilization and HRQoL of 3 categories children, e.g. children in the community with high scores (group 1), clinical ADHD children (group 2) and controls with low scores (group 3), at 4 moments in time (baseline, t = 6 months, t = 12 months and t = 18 months). The Child Health Questionnaire (CHQ-PF50) was used for measuring the HRQoL. Additionally, health care utilization and productivity loss of the mother of the respondents were assessed by using the Trimbos and iMTA questionnaire on Costs associated with Psychiatric illness' (TiC-P). RESULTS: At baseline, we distributed a total of 165 questionnaires for the 3 groups. The response rates were; group 1: 94% (n = 33), group 2: 90% (n = 64) and group 3: 78% (n = 47) respectively. Of group 1, 33% of the respondents were identified as ADHD by a paediatrician. Except for physical function, group 2 (ADHD patients) scored significant worse on social and emotional functioning and the health care costs were higher than group 1 and 3. CONCLUSIONS: Children suffering from ADHD had worse HRQoL and higher health care costs than the controls.
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PMH15 ANNUAL SOCIETAL COSTS AND QUALITY OF LIFE IN CHILDREN WITH NEUROPSYCHIATRIC DISORDERS IN SWEDEN
Myren KJ 1 , Gillberg C 2 , Nydén A 2 1 Eli Lilly Sweden AB, Solna, Sweden; 2 Göteborg University, Gothenburg, Sweden OBJECTIVES: The objective of the study was to calculate annual costs in children with AS/HFA, ADHD and RD/WD, and to explore which variables explained the variations in costs. METHODS: Sixty boys-20 with high-functioning autism or Asperger syndrome (AS/HFA), 20 with attention deficit hyperactivity disorder (ADHD) and 20 with reading and writing disorder (RD/WD)-participated in 1994 in an evaluation project in Göteborg, Sweden. In 2003, a second follow up was undertaken in 56 boys and their families. Cross sectional data on outpatient and inpatient care for the child, and indirect resource use for the families, e.g. time taken off from work and school assistance was collected through questionnaires. Local unit costs and prices were then applied to calculate annual costs. The parents also filled out the Child Health Questionnaire (CHQ-PF50). RESULTS: A total of 52 families responded to the questionnaires. The mean age was 18 years. The mean annual costs (SEK) were 67,000, of which indirect costs were 62,500 and direct costs 4500. Children with AS/HFA and ADHD had mean costs of 89,800 and 86,500, compared to 23,400 in children with RD/WD. Multiple regression analysis showed a strong correlation between costs and the psychosocial summary score of the CHQ: Total annual costs = 330,000 -5800 ¥ PsS (r = -0.70). Children with a PsS score below the median (47), had significantly higher total costs (SEK104,000 vs. 27,000) and indirect costs (SEK97,000 vs. 24,000) than children with scores above the median. CONCLUSIONS: These results emphasize that the indirect costs in child neuropsychiatric disorders are significant, representing more than 90% of the total costs. The variation in annual costs is explained, to a great extent, by psychosocial impairments. The results indicate that a treatment, which improves the psychosocial functioning of the child and family, may have significant potential in reducing family and societal costs. 
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